Latest Period
Q1 2026
Security Snapshot
Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR) Institutional Ownership
CUSIP: 929033207
13F Institutional Holders and Ownership History from Q3 2025 to Q1 2026
Institutions Reporting
80
Shares (Excl. Options)
40,448,699
Price
$17.84
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- VOR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 40,448,699
- Total 13F value
- $716,851,001
- Portfolio coverage rank
- 0%
- Share change
- +14,037,614
- Value change
- +$247,955,353
- Number of holders
- 80
- Shares outstanding
- 51,352,293
- SEC-reported price per share
- $17.25
- Insider filing price
- $17.25
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VOR - Vor Biopharma Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 929033207.
- 80 institutions reported positions in Q1 2026.
- 10 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 54 to 80 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $332,020,908 to $716,851,001.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 80 institutions filings for Q1 2026.
Security key
929033207
Latest holder period
Q1 2026
13F holders
80
13D/G owners
10
CIK / CUSIP context first
Open Q1 2026 holders
VOR full holder history
Vor Biopharma Inc. SEC filings
Vor Biopharma Inc. company facts
Vor Biopharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 929033207:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
10
Security
VOR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ForGrowth III PA B.V. | 10% | 0% | $81,492,203 | +$25,772,203 | 10,237,714 | +46% | ForGrowth III PA B.V. | 18 Dec 2025 |
| RA CAPITAL MANAGEMENT, L.P. | 14% | +41% | $43,075,707 | +$24,407,302 | 5,411,521 | +131% | RA Capital Management, L.P. | 18 Dec 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | 0% | $91,763,980 | +$51,763,826 | 5,083,877 | +129% | Venrock Healthcare Capital Partners III, L.P. | 31 Mar 2026 |
| Verve Capital Ltd | 9.3% | -6% | $90,236,860 | +$12,667,634 | 4,999,272 | +16% | Verve Capital Limited | 31 Mar 2026 |
| FMR LLC | 6.5% | -42% | $37,185,222 | +$25,579,283 | 2,526,170 | +220% | FMR LLC | 31 Dec 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5.8% | $17,973,688 | 2,258,001 | Frazier Life Sciences Public Fund, L.P. | 18 Dec 2025 | |||
| Paradigm Biocapital Advisors LP | 4.5% | -46% | $23,730,000 | 1,750,000 | 0% | Paradigm BioCapital Advisors LP | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC | 3.3% | -39% | $18,578,651 | +$1,839,021 | 1,370,107 | +11% | Great Point Partners, LLC | 31 Dec 2025 |
| Reprogrammed Interchange LLC | 18% | $48,045,191 | 1,204,442 | Reprogrammed Interchange LLC | 15 Oct 2025 | |||
| Qiming Venture Partners VIII-HC, L.P. | 2% | -27% | $19,670,294 | 1,089,767 | 0% | Qiming Venture Partners VIII-HC, L.P. | 31 Mar 2026 |
As of 31 Mar 2026, 80 institutional investors reported holding 40,448,699 shares of Vor Biopharma Inc. - Common Stock, $0.0001 par value per share (VOR). This represents 79% of the company’s total 51,352,293 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
74%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 11% | 5,673,078 | 2.8% | $96,499,052 | |
| RA CAPITAL MANAGEMENT, L.P. | 11% | 5,404,998 | 0% | 1% | $96,425,164 |
| FCPM III SERVICES B.V. | 8% | 4,117,354 | +14% | 10% | $73,453,595 |
| Venrock Adviser, LLC | 5.9% | 3,041,719 | +56% | 2% | $54,264,267 |
| Frazier Life Sciences Management, L.P. | 5% | 2,543,939 | 0% | 1.2% | $45,383,872 |
| Caligan Partners LP | 3.7% | 1,925,066 | +108% | 2.4% | $34,343,177 |
| Paradigm Biocapital Advisors LP | 3.4% | 1,750,000 | 0% | 0.64% | $31,220,000 |
| GREAT POINT PARTNERS LLC | 3.4% | 1,750,000 | +28% | 7.6% | $31,220,000 |
| FMR LLC | 3% | 1,539,670 | -39% | 0% | $27,467,713 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 1,433,280 | 0% | 0% | $25,569,715 |
| MARSHALL WACE, LLP | 2.2% | 1,153,276 | 0.02% | $20,574,444 | |
| STATE STREET CORP | 2.2% | 1,118,458 | +1128% | 0% | $19,953,291 |
| NEXTBio Capital Management LP | 1.9% | 999,967 | 0% | 8.3% | $17,839,411 |
| BlackRock, Inc. | 1.5% | 794,759 | +71% | 0% | $14,178,501 |
| Logos Global Management LP | 1.5% | 750,000 | +650% | 0.69% | $13,380,000 |
| Rosalind Advisors, Inc. | 1.4% | 700,000 | 5.1% | $12,488,000 | |
| BOOTHBAY FUND MANAGEMENT, LLC | 1.1% | 555,702 | 0.23% | $9,913,724 | |
| UBS Group AG | 0.95% | 488,368 | +67% | 0% | $8,712,485 |
| BRAIDWELL LP | 0.91% | 466,774 | 0.28% | $8,327,248 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.67% | 342,573 | +84% | 0% | $6,114,830 |
| Clearline Capital LP | 0.64% | 326,168 | 0.45% | $5,818,837 | |
| SPHERA FUNDS MANAGEMENT LTD. | 0.63% | 321,917 | -22% | 0.99% | $5,742,999 |
| Laurion Capital Management LP | 0.62% | 318,670 | +0.45% | 0.53% | $5,685,073 |
| Propel Bio Management, LLC | 0.61% | 314,543 | 3.5% | $5,587,368 | |
| GOLDMAN SACHS GROUP INC | 0.51% | 261,891 | +80% | 0% | $4,672,135 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
3
Latest
Q1 2026
Rows shown
1-3 of 3